美國肯堡(Kimble)
肯堡玻璃有限公司(英文名稱:Kimble Glass Inc.)成立于1901年,是一家注冊于美國商業登記處的有限責任公司。自1994起為格雷斯海姆集團有限責任公司(英文名稱:Gerresheimer Group GmbH)全資子公司。全球知名的肯堡玻璃有限公司為一家專門從事制藥、生物工藝和科研市場特種玻璃業務的倍受青睞的國際領先公司,是全球知名的高質量實驗室玻璃器皿產品的制造及分銷商。
肯堡玻璃有限公司在全球范圍內制造和分銷耐用性與一次性耗材類玻璃器皿,包括醫藥類、科研類、教育類專業玻璃器皿。
其業務范圍包括:醫藥用玻璃器皿;模壓玻璃;實驗室玻璃儀器;玻璃管棒材。制造和供應鏈管理技術的發展,以及市場上生物制藥和生物工藝技術的突飛猛進,令肯堡實驗器皿有限公司須不斷重組其業務經營。肯堡實驗器皿有限公司將一如既往地繼續進行其工藝再設計、更新其產能,以便為其客戶提供更優質的服務。
肯堡玻璃有限公司已拓展了其全球業務經營范圍,并攜手格雷斯海姆集團有限責任公司位于歐洲和拉丁美洲的其它19家制造廠提供全面的產品和服務系列。肯堡有能力完成其因大范圍合并而服務的以未來為導向的市場上常見的國際競標和承包工作。
北京博美華龍玻璃儀器有限公司2003年8月正式成立。是北京玻璃儀器廠和北京朝龍玻璃儀器有限公司合資的企業。 它是北京玻璃儀器廠燈工、磨口、刻度部份及該廠技術交流站與民營企業朝龍玻璃儀器有限公司合資組建。北京博美華龍玻璃儀器有限公司的成立,集中了國企設備優勢和人才優勢以及五十年的生產經驗,傳承了玻璃儀器生產的精髓,同時也保留了民營企業吃苦耐勞,對用戶全心全意的工作作風。生產產品為博美”牌硼硅玻璃制品、實驗玻璃器皿及生物和醫藥用玻璃產品等。合資組建以來,管理水平不繼提高,生產規模日益擴大,產品遠銷國內外市場。兩強攜手共建的肯堡博美(北京)實驗器皿有限公司是一家有限責任公司,各方以各自認繳的出資額對合資公司的債務承擔責任,各方按其出資額在注冊資本中的比例分享利潤,承擔風險和虧損。合資公司利用北京博美華龍玻璃儀器有限公司現有條件和構筑的發展平臺,和從格雷斯海姆集團有限公司引入技術、管理及國際銷售網絡,取得優良的經濟效益,最終使合資公司成為全球領先的硼硅玻璃實驗室儀器供應商,通過我們長期的努力,用我們世界級的產品品質與服務來贏得優厚的回報。
Specialists in Producing Glass
Kimble Glass Inc. is a respected global leader in specialized glass for the pharmaceutical,
biotechnology and scientific research markets. We are a customer-driven company, dedicated
to the continuous improvement in manufacturing and the highest quality of products and
services.
Strong Market Position
Our strategic thrust has been to back our innovation and service positions with strong account
management and service integrity. As a result, we have maintained strong loyal customer
relationships, which are key to our businesses.
International Presence
Kimble has expanded its worldwide scope of activities. Combined with 16 other Gerresheimer
Group manufacturing plants in Europe and Latin America, Kimble provides comprehensive
product and service options. We are able to fulfill competitive global bids and contracts that
are now commonplace in the future-oriented markets we serve due to extensive consolidation.
Strategic Focus
The company was founded in 1901 and has belonged to Gerresheimer Glass AG since 1994.
Today, as we commemorate our centennial year, we are at yet another milestone. Technological
advances in manufacturing and supply chain management along with significant leaps in
biopharmaceutical and biotechnological breakthroughs in the markets we serve require constant
restructuring of our businesses. As in the past, we will continue to re-engineer our processes
and update our capabilities and capacity to better serve our customers. The new owners have
considerable financial strength and long term interest in continuing the successful strategy of
the Gerrresheimer Group.